In the third quarter, diluted net income per share was $1.28 per share and adjusted EBITDA was $77 million.
On a consolidated basis, the company reported net sales for the third quarter of $457 million and adjusted EBITDA of $77 million, which represents growth of approximately 3% and 145% respectively over the third quarter of last year.
It is estimated that $1 retail sales grew 34% in the first quarter, 23% in the second quarter and 12% in the third quarter.
Depreciation is expected to be between $109 million and $112 million.
Our sales in the third quarter were 14.5 million cases, representing a unit decline of 9% versus the second quarter and unit growth of 10% versus prior year as expected.
If assumptions around demand as well as largely stable prices and raw material inputs hold, we would anticipate fourth quarter adjusted EBITDA to be in the range of $52 million to $62 million.
In the third quarter, we used the free cash flows generated to reduce our net debt by an additional $40 million and we refinanced our 2023 notes with a new 2028 notes.
During our last quarter's call, we anticipated the IRI panel data to be up in the 10% to 15% range in the third quarter and it was close to 12%.
Planned major outage expenses are expected to reduce our earnings in 2021 compared to 2020 by $25 million to $30 million.
Capital expenditures are trending toward $45 million and we still do not expect to be a net cash taxpayer in 2020.
Together with our NuVo SBS brand of cup stock with up to 35% post-consumer recycled fiber, we're meeting our customers and consumer preferences for more recycled content in an already highly sustainable form of paper-based packaging without compromising on consumer safety and product quality.
We shipped 14.5 million cases, which was up around 10% compared to the third quarter of 2019, but down 9% over the second quarter of 2020, as expected.
We've updated this guidance on slide 22, which represents a slight increase relative to prior guidance of $23 million to $27 million.
Our October shipments were around 4 million cases, which is down from an average of 4.8 million cases per month in the third quarter of 2020 and 4.4 million cases per month in the fourth quarter of 2019.
Our production in the quarter was 15.3 million cases, were down 4% versus the second quarter and up 19% versus prior year.
Interest expense between $46 million and $48 million, which is a slight decrease to the past expectations due to debt repayments.